Iktos acquires Synsight, a life sciences know-how firm specializing in protein-protein and RNA-protein interactions-targeted drug discovery


Iktos acquires Synsight, a life sciences know-how firm specializing in protein-protein and RNA-protein interactions-targeted drug discovery

  • Synsight gives Iktos with an unique worldwide license to INSERM’s patented know-how enabling excessive efficiency AI-driven in cellulo screening of modulators of protein-protein and RNA-protein interactions
  • The merger additional enhances Iktos’ AI-based drug discovery platform, that at the moment consists of generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by including the important thing step of automated organic testing

Paris, July 8th 2024 Iktos, an organization specializing in Synthetic Intelligence (AI) and Robotics for brand spanking new drug design, broadcasts the acquisition of Synsight, a French biotech firm making use of AI and high-content cell imaging to the invention of novel drug candidates. The operation completes Iktos’ distinctive platform in AI and Robotics-assisted drug discovery.

Strengthening Iktos’s drug discovery worth chain

Below an unique license from INSERM, Synsight has developed MT Bench™, a know-how that detects protein-protein (PPI) and RNA-protein interactions (RPI) in cellulo with unprecedented efficiency and allows the screening of molecules that may modulate these interactions.

Iktos, a number one European firm in GenAI for Drug Discovery with a robust observe file of profitable collaborations with biopharmaceutical firms, is creating Iktos Robotics, a singular AI-driven robotic synthesis platform to speed up and automate drug discovery, to date a extremely guide and useful resource intensive course of.

As well as, the combination of Synsight’s MT Bench know-how will convey a key complementary ingredient to the Iktos Robotics platform: the organic testing of synthesized compounds. Synsight additional strengthens Iktos’ drug discovery worth chain, enabling the corporate to internalize organic testing which has been outsourced till now thus additional speed up the design-make-test course of.

The mixing may even allow Iktos to launch drug discovery packages focusing on PPI’s and RPI’s, which play a essential function in lots of ailments equivalent to most cancers and neurodegenerative ailments.

Synsight’s screening platform that advantages from AI, mobile imaging and robotization, is according to Iktos’ ambition to construct an end-to finish AI- and Robotics-enabled discovery platform

Based by Cyril Bauvais, and Guillaume Bollot, Synsight, a member of the Genopole biocluster, relies on the Evry Genopole and operates a joint laboratory with Université Evry Paris Saclay (UMR 1204 SABNP laboratory). The corporate makes use of mobile imaging, AI and robotization to drive the invention of PPI- and RPI-targeted drug candidates.

This acquisition is a vital milestone for Iktos”, acknowledged Yann Gaston-Mathé, co-founder and CEO of Iktos. “Iktos, a pacesetter in AI-driven Drug Discovery, unlocks bottlenecks in difficult packages and accelerates identification of drug candidates. The acquisition of Synsight allows Iktos to develop its platform to new modulators of PPI’s and RPI’s, traditionally extremely difficult targets, thereby addressing main unmet medical wants in varied therapeutic areas equivalent to most cancers and neurodegenerative ailments.”

Alexis Denis, SVP, Head of Drug Discovery at Iktos, declared: “PPI and RPI are two essential goal households as they regulate main organic mechanisms and play a serious function in lots of ailments. They’re very promising, however extremely difficult targets and notoriously arduous to drug. Synsight’s MT Bench know-how platform is a unbelievable software to review these interactions and determine novel molecules to modulate these targets. Mixed with Iktos Generative AI know-how and Robotics platform, we’re assured that we’ll have a singular software to make breakthroughs on this difficult however very promising subject.”

Cyril Bauvais, co-founder and President of Synsight, declared:I’m very pleased to change into a part of the Iktos crew and on the perspective of including our platform to construct a one-of-its-kind drug discovery engine. Iktos superior generative AI and retrosynthesis AI know-how mixed with our experience in excessive content material mobile screening and detection of molecular interactions inside the cell will present us with a aggressive benefit in focusing on PPIs and RPIs. I, in addition to the entire Synsight crew, sit up for a profitable collaboration with our new colleagues.”

About Iktos

Iktos is a French start-up firm specializing in synthetic intelligence and robotic options utilized to analysis in medicinal chemistry and new drug design. Iktos is creating a proprietary and modern generative AI answer which allows the design of molecules which are optimized in silico to satisfy all of the success standards of a small molecule discovery undertaking. Using Iktos know-how allows main productiveness good points in upstream pharmaceutical R&D. Iktos gives its know-how by the SaaS software program platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and thru strategic collaborations with pharma firms the place Iktos mobilizes its distinctive platform and modern capabilities to expedite small molecule drug discovery for the advantage of its companions. Iktos has additionally developed Iktos Robotics, a singular AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Check-Analyze cycle in drug discovery and is creating its personal pipeline of drug candidates focusing on oncology and auto-immune and inflammatory ailments. In March 2023, Iktos accomplished a 15.5M€ Collection A financing spherical co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital.

Extra data on: https://www.iktos.ai/

About Synsight

SYNSIGHT is a French firm specialised in discovery and growth of therapeutic molecules, particularly focusing on protein-RNA interactions. Due to its discovery platform, on the convergence of synthetic intelligence and mobile imaging, SYNSIGHT develops a portfolio of proprietary and partnered small molecule therapeutic initiatives.

About Protein-Protein interactions and RNA-Protein interactions targets

Inside residing cells, all macromolecules: proteins, RNA, DNA work together collectively inside complicated and interconnected networks through a number of interactions which play a elementary function in any respect ranges of the cell. Metabolism, signaling and cell proliferation, intercellular communication and even the upkeep of membrane structure are notably regulated by quite a few linked to protein-protein interactions (PPI). The identical is true for the massive household of proteins that work together with RNA. Certainly, the destiny of coding and non-coding RNAs (stability, trafficking within the cell) may be very strongly related to the interactions of RNAs with these proteins (RPI). The seek for small molecules that particularly disrupt these networks and interactions due to this fact constitutes a really promising subject for creating new focused therapies, notably in oncology and neurodegenerative ailments.

About MT Bench™

The MT Bench (Microtubule Bench) know-how was initially developed at INSERM, and additional developed by Synsight by the applying of lab automation, robotics, high-content imaging and AI/ML to allow screening and optimization of drug molecules. It makes use of the mobile microtubule community as a bench to detect and quantify protein-protein and protein-RNA interactions, offering useful qualitative and quantitative knowledge in a mobile context. The MT Bench is especially modern as a result of it permits for the direct commentary of how small molecules modulate these interactions, making it doable to evaluate compound efficacy straight from contained in the cell. That is essential for an correct understanding of the habits of potential drug candidates in a biologically related atmosphere. Within the subject of RNA-targeting drug discovery, the place exact and efficient focusing on of RNA-protein interactions has been a serious problem, this makes MT Bench a singular and invaluable software with groundbreaking potential.



Yann Gaston-Mathé (CEO) – contact@iktos.com

Ulysse Communication
Nicolas Daniels – ndaniels@ulysse-communication.com / + 33 6 63 66 59 22
Charles Courbet – ccourbet@ulysse-communication.com / + 33 6 28 93 03 06



Primary Logo

Leave a Comment